Beiersdorf Confirms Outlook After Challenging Start to the Year
By Andrea Figueras
Nivea-maker Beiersdorf maintained its guidance for the current year after posting a decrease in first-quarter sales.
The German cosmetics company on Tuesday logged quarterly sales of 2.48 billion euros ($2.92 billion), down 4.6% organically compared with the same period a year prior.
The dermatology business continued to perform strongly, while Nivea and La Prairie recorded unfavorable results. However, better sales trends indicate an improvement over the coming quarters, it said.
The performance during the first three months of the year was impacted by a high comparison base in the prior-year period, temporary disruptions in key markets, and delayed effects from recent innovations, Chief Executive Vincent Warnery said. These factors are not expected to persist throughout the year, he said, noting that the first quarter shouldn't be seen as an indicator for the full-year performance.
For 2026 as a whole, the company continues to expect group net sales to be flat to slightly growing organically, with the earnings before interest and taxes margin excluding special factors slightly below the 2025 level.
Write to Andrea Figueras at andrea.figueras@wsj.com
(END) Dow Jones Newswires
April 21, 2026 02:36 ET (06:36 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States